Evidence map›Paper›PMID 34494019›Full record

ArticlebioRxiv : the preprint server for biology2021

Weakly activated core inflammation pathways were identified as a central signaling mechanism contributing to the chronic neurodegeneration in Alzheimer's disease.

Fuhai Li, Abdallah Eteleeb, William Buchser, Guoqiao Wang, Chengjie Xiong, Philip R Payne, Eric McDade, Celeste M Karch, Oscar Harari, Carlos Cruchaga

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Fuhai LiInstitute for Informatics (I2), Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA.
Abdallah EteleebDepartment of Psychiatry, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA.
William BuchserDepartment of Neuroscience, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA.
Guoqiao WangDivision of Biostatistics, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA.
Chengjie XiongDivision of Biostatistics, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA.
Philip R PayneInstitute for Informatics (I2), Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA.
Eric McDadeDepartment of Neurology, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA.
Celeste M KarchDepartment of Psychiatry, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA.
Oscar HarariDepartment of Psychiatry, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA.
Carlos CruchagaDepartment of Psychiatry, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA.
Washington University in St. Louis · US

Funding

Smartphone-Based "Burst" Cognitive AssessmentsP01AG003991 · NIA · WASHINGTON UNIVERSITY · PI JOHN MORRIS · 1985 to 2026
$69.5M
MENDELIAN RANDOMIZATION FOR UNBIAS BIOMARKER DISCOVERY FOR AD AND OTHER COMPLEX TRAITSR01AG057777 · NIA · WASHINGTON UNIVERSITY · PI HARARI, OSCAR · 2018 to 2022
$4.1M
USING QUANTITATIVE TRAITS TO IDENTIFY NOVEL GENES FOR ALZHEIMERS DISEASE AND OTHER COMPLEX TRAITSRF1AG053303 · NIA · WASHINGTON UNIVERSITY · PI CLIMER, SHARLEE, CRUCHAGA, CARLOS · 2016 to 2020
$4.0M
GENETIC MODIFIERS OF CEREBROSPINAL FLUID TREM2 IN ALZHEIMER'S DISEASERF1AG058501 · NIA · WASHINGTON UNIVERSITY · PI CRUCHAGA, CARLOS, PICCIO, LAURA · 2018 to 2018
$3.5M
The Familial Alzheimer Sequencing (FASe) ProjectU01AG058922 · NIA · WASHINGTON UNIVERSITY · PI CRUCHAGA, CARLOS, GOATE, ALISON M · 2018 to 2022
$3.5M
IDENTIFYING RARE VARIANTS THAT INCREASE RISK FOR ALZHEIMER'S DISEASER01AG044546 · NIA · WASHINGTON UNIVERSITY · PI CRUCHAGA, CARLOS · 2013 to 2017
$2.7M
Combine Genomics and Symptoms Data Driven Models to Discover Synergistic Combinatory Therapies for Alzheimer's DiseaseR56AG065352 · NIA · WASHINGTON UNIVERSITY · PI LI, FUHAI · 2020 to 2021
$986k
NIA NIH HHS P01 AG003991NIA NIH HHS R01 AG044546NIA NIH HHS R01 AG057777NIA NIH HHS R56 AG065352NIA NIH HHS RF1 AG053303NIA NIH HHS RF1 AG058501NIA NIH HHS U01 AG058922
6 · The paper itself

Abstract

Neuro-inflammation signaling has been identified as an important hallmark of Alzheimer's disease (AD) in addition to amyloid β plaques (Aβ) and neurofibrillary tangles (NFTs). However, our knowledge of neuro-inflammation is very limited; and the core signaling pathways associated with neuro-inflammation are missing. From a novel perspective, i.e., investigating weakly activated molecular signals (rather than the strongly activated molecular signals), in this study, we uncovered the core neuro-inflammation signaling pathways in AD. Our novel hypothesis is that weakly activated neuro-inflammation signaling pathways can cause neuro-degeneration in a chronic process; whereas, strongly activated neuro-inflammation often cause acute disease progression like in COVID-19. Using the two large-scale genomics datasets, i.e., Mayo Clinic (77 control and 81 AD samples) and RosMap (97 control and 260 AD samples), our analysis identified 7 categories of signaling pathways implicated on AD and related to virus infection: immune response, x-core signaling, apoptosis, lipid dysfunctional, biosynthesis and metabolism, and mineral absorption signaling pathways. More interestingly, most of genes in the virus infection, immune response and x-core signaling pathways, are associated with inflammation molecular functions. Specifically, the x-core signaling pathways were defined as a group of 9 signaling proteins: MAPK, Rap1, NF-kappa B, HIF-1, PI3K-Akt, Wnt, TGF-beta, Hippo and TNF, which indicated the core neuro-inflammation signaling pathways responding to the low-level and weakly activated inflammation and hypoxia, and leading to the chronic neuro-degeneration. The core neuro-inflammation signaling pathways can be used as novel therapeutic targets for effective AD treatment and prevention.

Identifiers

PMID34494019
PMCPMC8423192
OpenAlexW3198881416

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.